/
MOLN
$3.96+$0.16 (+4.21%)prev close
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$142.5M
38M shares
52-week range
$3.41 – $5.36
28% from low
Exchange
NASDAQ
ADRC
Borrow rate
5.41%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-16.34
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $10.4M | $20.4M | $9.3M | $9.3M | $189.6M | $7.0M | $5.0M | $0 |
| Cost of revenue | $15.6M | $43.5M | $56.1M | $55.7M | $50.7M | $47.8M | $47.5M | $2.0M |
| Gross profit | −$5.2M | −$23.1M | −$46.7M | −$46.4M | $138.8M | −$40.8M | −$42.5M | −$2.0M |
| Gross margin | -50.7% | -113.4% | -500.1% | -497.2% | 73.2% | -579.8% | -855.8% | — |
| R&D | $38.2M | $43.5M | $56.1M | $55.7M | $50.7M | $48.8M | $48.6M | $40.2M |
| Operating income | −$37.4M | −$36.7M | −$58.3M | −$63.4M | $116.6M | −$61.1M | −$61.2M | −$58.1M |
| EBITDA | −$36.1M | −$33.7M | −$59.6M | −$60.7M | $119.0M | −$59.5M | −$51.6M | −$59.5M |
| Net income | −$37.0M | −$36.3M | −$62.8M | −$63.8M | $117.9M | −$62.0M | −$54.0M | −$61.7M |
| Net margin | -357.7% | -178.0% | -671.7% | -683.7% | 62.2% | -880.7% | -1087.4% | — |
| EPS (diluted) | -1.75 | -1.69 | -2.51 | -2.06 | 3.54 | -1.89 | -1.59 | -1.65 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $11M | $-1.47 | $-2.07–$-0.88 | 2 |
| 2027 | $62M | $-1.35 | $-6.10–$8.12 | 2 |
| 2028 | $1M | $-1.55 | $-1.76–$-1.34 | 2 |
| 2029 | $34M | $-1.48 | $-1.48–$-1.48 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$2.65
Price
$3.96
Implied downside
-33%
Peer comparison
Molecular Partners AG American Depositary Shares
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.
www.molecularpartners.com- Employees
- 134
- IPO / List date
- Jun 16, 2021
Held by traders on TradeandTell
No one on the platform currently holds MOLN.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in MOLN as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded MOLN yet.
